Coronavax is developing CVAX-001, an intranasal therapeutic that reprograms the immune response to target persistent symptoms of Long COVID, which affects an estimated 100 million people globally. By applying Immuno-Oncology principles, the company aims to enhance mucosal immunity and eliminate the virus hidden in hard-to-reach tissues, improving patients' quality of life.
Funding
$660K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Long COVID, affecting millions globally, presents persistent symptoms long after the initial infection clears. Current treatment options are limited, and the virus's ability to hide in tissues that are difficult to reach complicates therapeutic interventions. The condition significantly impacts quality of life and carries substantial economic costs.
Solution
Coronavax is developing CVAX-001, an intranasal therapeutic designed to reprogram the immune response to target the underlying causes of Long COVID. Drawing inspiration from immuno-oncology, CVAX-001 aims to enhance mucosal immunity, enabling the immune system to target and eliminate the virus in hard-to-reach tissues without causing excessive inflammation. The therapeutic approach focuses on addressing the inflammatory condition resulting from the immune system's incomplete viral clearance, offering a potential solution for individuals with persistent Long COVID symptoms. By stimulating the immune system to target the virus, Coronavax seeks to improve patients' quality of life and provide a more effective treatment option.
Target Audience
The primary target audience includes individuals suffering from persistent Long COVID symptoms and healthcare providers seeking innovative therapeutic options for this condition.
Features
- Intranasal administration for targeted delivery to mucosal tissues.
- Immunomodulatory mechanism designed to reprogram the immune response.
- Focus on enhancing mucosal immunity to eliminate persistent virus.
- Application of immuno-oncology principles to address Long COVID.